Plain-English translation of NCT03970096 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer approach called selective T-cell depletion—where doctors carefully remove certain immune cells from the donor graft before transplant—works better than post-transplantation (a chemotherapy drug given after transplant) for preventing a serious complication called graft-versus-host disease. Both strategies are designed to reduce the risk of the donor's immune system attacking your body after a stem cell transplant. The trial will help doctors understand which approach gives the best outcomes for people with acute leukemia or myelodysplastic syndrome.
Graft-versus-host disease is one of the most serious complications after donor stem cell transplant and can cause life-threatening damage to multiple organs. Doctors want to find the safest and most effective way to prevent this complication while still allowing the transplant to work against the cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. Before your transplant, you'll receive several days of chemotherapy and/or radiation to prepare your body. Then you'll receive donor stem cells through an IV, followed by either special immune cells that have been filtered to reduce rejection risk, or a chemotherapy medication given a few days after transplant. You'll also receive medications by IV to help prevent rejection and stay in the hospital for several weeks during recovery. Throughout the trial, you'll have regular blood tests, bone marrow biopsies, heart imaging, and follow-up visits to monitor your progress and watch for complications.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States